CV: Curriculum Vitae

Thomas M. Banas, M.D., M.S.

Discerning M.D., Inc.

11230 Dell Loch Way

Fort Wayne, IN 46814

Email: Thomas.Banas@discerningmd.com

Cell phone: (260) 466-1752

 

EXPERIENCE

 

  • July 1992-August 2020: Neurologist, Fort Wayne Neurological Center.  Expertise in stroke, epilepsy, TBI, concussion, neurological rehabilitation, movement disorders, spasticity and general neurology.

  • May 2021-present: Tele-neurology

  • August 2020-present Locums Neurology 

  • 1997-present: Independent Medical Examiner.

 

  • 1997-2020: Assistant Professor Clinical Medicine, Indiana Medical School, Fort Wayne, Indiana.

 

  • July 2017-August 2020: Research Director, Fort Wayne Neurology.

 

  • June 2015-2019: Board Member, Chair of Indiana Neurological Society (INS) Membership Committee.

 

  • 2018-2021: Executive Committee of American Neurological Society Industrial Relations Committee.

 

  • 2016-present: Board of Directors Committee, Turnstone Center, Fort Wayne, Indiana.

 

  • 2017-present: Committee Member, Young Life, Southwest of Fort Wayne.

  • 1992-2016: Parkview Regional Medical Center Research Center, Fort Wayne, Indiana.

 

  • 2010-2013: Medical Director/Chairman Rehab Hospital of Fort Wayne, Indiana.

 

  • 2008-2012: Director of Neuroscience, Department of Medical Education, IPFW School of Medicine, Fort Wayne, Indiana.

 

  • 2005-present: Stroke Care Now Network/Acute Stroke, Network of 27 Hospitals.  Physician/Neurologist.

 

  • 2009-2012: Stroke Director, Stroke Care Now Network, Northern Indiana.

 

  • 1992-2016:  Neurologic Rehabilitation Patient Care.

 

EDUCATION

 

POST-GRADUATE TRAINING

 

  • University of Cincinnati Medical Center, Neurology Resident, 1989-1992.

 

  • University of Cincinnati Medical Center, Department of Internal Medicine, Internship, Cincinnati, Ohio, 1988-1989.

 

  • University of Cincinnati School of Medicine, Cincinnati, Ohio, 1984-1988.

 

  • Case Western Reserve University Biomedical Engineering, Master of Science, Cleveland, Ohio, 1982-1984.

 

  • Case Western Reserve University Biomedical Engineering, Bachelor of Science, Cleveland, Ohio, 1977-1982.

 

  • University of Sussex, Falmer-Brighton, England, Junior Year 1979-1980.

 

 

HONORS AND AWARDS

 

1977                                  Case Western Alumni Scholar

                                          Michigan Regent Alumni Scholar

 

1982                                  B.S. Degree in Biomedical Engineering with Honors

 

1984                                  M.S. Degree in Biomedical Engineering with High Honors

 

CURRENT MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

 

  • American Academy of Neurology

  • American Board of Psychiatry & Neurology, Inc.

  • Ohio State Medical Association

  • Indiana State Medical Association

  • Fort Wayne Medical Association

 

 

MEDICAL LICENSE

 

  • State of Ohio (Permanent), ID #35.059816

  • State of Indiana, ID #01040131

  • State of Michigan, ID #M521386

  • State of North Carolina ID #260585

  • State of Arkansas ID #T2021-2022

 

THESIS

 

  • Completion of Master's thesis entitled "Internal Changes in Muscle Gain Induced by Submaximal Intermittent Exercises."

 

HOSPITAL AFFILIATIONS

 

  • Parkview Hospital, Fort Wayne, Indiana

  • St. Joseph Medical Center, Fort Wayne, Indiana

  • Lutheran Hospital, Fort Wayne, Indiana

  • Dupont Hospital, Fort Wayne, Indiana

  • Rehabilitation Hospital of Fort Wayne, Indiana

  • Wabash Hospital, Wabash, Indiana

  • Baptist Hospital, little Rock, Arkansas

  • Novant, North carolina

 

 

EMPLOYMENT PRIOR TO RESIDENCY

 

6/85 - 9/85                  Consultant Engineer, Department of Physiology, University of Cincinnati, Cincinnati, Ohio

 

4/84-9/94                    Engineer, Gait Laboratory, Veterans Administration Center, Cleveland, Ohio

 

9/83-4/84                    Engineer, Rehabilitation Engineering Center/CWRU, Department of Orthopedics, Highland View Metro General Hospital, Cleveland, Ohio

 

1/78-9/81                    Research Assistant, Applied Neural Control Laboratory, Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio

 

Special Training

 

Collaborative Institutional Training Initiative (CITI)

 

CLINICAL TRIALS/RESEARCH

 

2019                  UCB Biopharma SPRL - A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy, Sub-Investigator

2018                  Acadia Pharmaceuticals  ACP-NIS-001 - An Observational Study on the Management of Parkinson's Disease Psychosis in Actual Practice,  Primary Investigator

2018                  F. Hoffmann - LaRoche - A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease, Sub-Investigator

2018                  Alexion EC-NMO-302 - A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO), Sub-Investigator

2015                  Alexion EC-NMO-301 - A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center trial to evaluate the safety and efficacy of Eculizumab in patients with Neuromyelitis Optica (NMO), Sub-Investigator

2015                  Biogen 101MS413 - A Phase IV Multicenter, Open-Label study to evaluate whether a Medication Event Monitoring System (MEMS®) can improve adherence to Tecfidera (delayed-release dimethyl fumarate) treatment in MS patients, Sub-Investigator

2014                  Biogen 101MS409 - A Phase III Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis, Sub-Investigator

2013                  Sanofi Aventis LPS13567 - A Prospective, Single-Arm, Clinical-Setting, Study to Describe Efficacy, Tolerability and Convenience of AUBAGIO Treatment Using Patient Reported Outcomes in Relapsing Multiple Sclerosis Patients

2013                  Teva LAQ MS 305 - A multinational, multicenter, randomized, double blind, parallel Group placebo controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of Laquinimod in subjects with Relapsing Remitting Multiple Sclerosis

2011                  Pfizer, Inc.: A0081242- A phase 3B multicenter, double-blind, randomized withdrawal efficacy and safety study of Pregabalin in the treatment of patients with inadequately treated painful diabetic peripheral neuropathy, Principal Investigator

2010                  Biogen Idec: 101MS325 - A multicenter, randomized, rater-blind, parallel-group, active controlled study to evaluate the benefits of switching therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in subjects with relapsing remitting multiple sclerosis, Sub-Investigator

2010                Sanofi-Aventis:  EFC6058 - A multicenter, double-blind, parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta, Sub-Investigator

2010                Sanofi-Aventis:  LTS6050 - A long-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple sclerosis with relapses, Sub-Investigator

2010                Biogen Idec: 205MS301 - A multicenter, double-blind randomized, parallel-group monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in patients with relapsing-remitting multiple sclerosis, Sub-Investigator

2010                Biogen Idec: 101JC402 - A JCV antibody program in patients with relapsing multiple sclerosis receiving or considering treatment with Tysabri®, STRATIFY-2, Sub-Investigator

2009                Cephalon: C10953/3067 - An open-label study to evaluate the safety, tolerability, and efficacy of armodafinil (150 and 250) mg/day) as treatment for patients with

excessive sleepiness associated with mild or moderate closed traumatic brain injury, Sub-Investigator

2009                Octapharma: GAM-10-04, double-blind, randomized, multicenter, placebo-controlled dose-finding study evaluating the amyloid beta reduction in the cerebrospinal fluid and increase in the blood plasma after treatment with intravenous immunoglobulin in mild to moderate Alzheimer's disease, Sub-Investigator

2008                  Sanofi-Aventis: EFC10531 - A multi-center, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis using Interferon-Beta 1a (Rebif®) as an open-label rater-blind calibrator, Sub-Investigator

2008                  UCB: RPCE07F1214-historical-control conversion to monotherapy to evaluate the efficacy and safety of brivaracetam, with partial onset seizures with or without secondary generalization, Principal Investigator.

2008                  UCB: RPCE08C0502-follow-up study to evaluate the long-term safety and efficacy of brivaracetam used at flexible dose up to a max of 150 mg/day, Principal Investigator

2008                  Sanofi-Aventis: EFC6260 - An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis, plus a long-term extension period, Sub-Investigator

2007                  Sanofi-Aventis: EFC6049, a randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of a teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses, Sub-Investigator

2007                  Alza: C2006-028-03 - A single dose JNJ-17216498 for narcolepsy patients, Sub-Investigator

2007                  Eisai, Inc.:  E2020-G300-328 - Double-blind, parallel group comparison of 23 mg Donepezil sustained release to 10 mg Donepezil immediate release in patients with moderate to severe Alzheimer's Disease, Sub-Investigator

2007                  Eisai, Inc.: E2020-G300-326 - A comparison of 23 mg Aricept SR with 10 mg Aricept IR in patients with moderate to severe Alzheimer's disease, Sub-Investigator

2007                  Sanofi-Aventis: Teriflunomide in patients with relapsing MS, Sub-Investigator

2007                  Sanofi-Aventis: Teriflunomide in patients with a first clinical episode suggestive of multiple sclerosis, Sub-Investigator

2007                  Teva: PM028 - Evaluate the effect of regularly scheduling neutralizing antibody testing on treatment patterns versus usual care in IFN treated patients, Principal Investigator

2007                  SAPPHIRE: Registry for carotid stenting with the PRECISE stent system and angioplasty with protection in patients at high risk for endarterectomy,  Sub-Investigator

2007                  SONOMA: Registry for carotid stenting with the NexStent system in conjunction with the FilterWire EZ embolic protection system, Sub-Investigator

2006                  NTI: NTI-ASP-0502- A Viprinex (Ancrod) for acute ischemic stroke patients administered within 6 hours of onset, Sub-Investigator

2006                  Biogen Idec: Serologic study to correlate B-IFN NAb titers to B-IFN induced biomarker response in MS patients, Sub-Investigator

2006                  Depomed: 81-0045: Gabapentin Extended Release in treatment of patients with post-therapeutic neuralgia, Principal Investigator

2005                  Abbott: ABT-874 M03-654 - A compound ABT874 for patients with Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis, Sub-Investigator

2005                  Biogen Idec: C-870: Avonex for patients with CIDP, Sub-Investigator

2005                  Chant: 72-hour infusion for Intracranial Hemorrhage, Sub-Investigator

2005                  NMT Medical: Closure I: Starflex Closure system in patients with Patent Foramen Ovale, Principal Investigator

2005                  Forest: Bolus of thrombolytic in Acute Ischemic Stroke, Sub-Investigator

2005                  ONO: Neuroprotective infusion for Acute Ischemic Stroke, Sub-Investigator

2005                  Pfizer:  Neuroprotective infusion for Acute Ischemic Stroke, Sub-Investigator

2005                  Saint II: Neuroprotective infusion for Acute Ischemic Stroke, Sub-Investigator

2004                  Sceptre: NS2330 in early Parkinson's patient, Sub-Investigator

2004                  Biogen Idec: C865-Avonex, Methotrexate or IV Methylprednisolone in Relapsing-Remitting Multiple Sclerosis, Sub-Investigator

2003                  ACT: Avonex, Methotrexate or IV Methylprednisolone in Relapsing-Remitting Multiple Sclerosis, Sub-Investigator

2003                  Bayer: Above: Betaseron vs. Avonex Relapsing-Remitting Multiple Sclerosis, Sub-Investigator

2003                  CREST: Carotid Revascularization Endarterectomy vs. Stenting, Sub-Investigator

2003                  Orphan: Treatment of narcolepsy patients with Xyrem, Sub-Investigator

2002                  Schwarz: SP512 - Rotigotine in early stage Parkinson's disease, Principal Investigator

2002                  Schwarz: SP650 - Rotigotine in advance stage Parkinson's disease, Sub-Investigator

2001                  Bayer: Beyond: Betaseron vs. double dose Betaseron vs. Copaxone in relapsing-remitting multiple sclerosis, Sub-Investigator

2002                  Evaluate Patients with Acute Stroke given Tissue Plasminogen Activator + YM872

2002                  ARTIST MRI Acute Stroke-Evaluate Effects of YM872 Infusions on lesion volume

2002                  Elan Epilepsy Study, Principal Investigator

2002                  Deep Brain Stimulator for Parkinson's Disease Indiana University Purdue University Fort Wayne

2002                  Pfizer Alzheimer's Disease Study, Sub-Investigator

2002                  Security Carotid Stent Study, Sub-Investigator

2001                  Tolerability of Rebif injections with use of Rebiject device in relapsing-remitting multiple sclerosis patients

2001                  Mitoxantrone: Study of Side Effects in Multiple Sclerosis

2001                  Zonegran as Monotherapy in patients with newly diagnosed Epilepsy: Principal Investigator

2001                  Oral CP-457, 920 and Donepezil in Outpatients with Alzheimer's disease.

2000                  ASTA-MEDICA Chronic Pain, Sub-Investigator

2001                  Pfizer-Stroke Treatment Study 0-6 hour window, Sub-Investigator

2001                  ARTIST MRI Acute Ischemic Stroke Study. Sub-Investigator

2001                  ARTIST + Acute Ischemic Stroke Study, Sub-Investigator

2001                  Immunex Multiple Sclerosis Study, Sub-Investigator

2001                  IDE Carotid Stent Study, Sub-Investigator

1998                  Stroke Treatment with Ancrod Trial, 0-3 hour window, Sub-Investigator

1998                  Thrombolytic Therapy in Acute Ischemic Stroke (rt-PA) 0-3 hour window, Sub-Investigator

1998                  Gabitril Monotherapy Seizure Study

1998                  GAIN III Stroke Treatment Study, 0-6 hour window, Principal Investigator

1997                  COP-1 Treatment study 3-5 hour window, Sub-Investigator

1997                  Atlantis Stroke Treatment Study, 3-5 hour window, Sub-Investigator

1997                  Topiramate Epilepsy Trial, Sub-Investigator, Study closed by sponsor

1997                  Gain II Stroke Treatment Study, 0-12 hour window, Sub-Investigator

1997                  Fiblast Stroke Treatment Study, 0-6 hour window, Sub-Investigator

1997                  M.I.N.T. Alzheimer Study, Principal Investigator